Items where authors include "Danson, S."

Export as [feed] Atom [feed] RSS
Number of items: 55.

Article

Pan, X., AbdulJabbar, K. orcid.org/0000-0002-4411-4435, Coelho-Lima, J. et al. (276 more authors) (2024) The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Nature Cancer. ISSN 2662-1347

Dayimu, A. orcid.org/0000-0001-9998-7463, Gupta, A., Matin, R.N. et al. (25 more authors) (2024) A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). European Journal of Cancer, 196. 113455. ISSN 0959-8049

Hapuarachi, B., Danson, S. orcid.org/0000-0002-3593-2890, Wadsley, J. orcid.org/0000-0002-1499-1277 et al. (1 more author) (2023) Exercise to transform tumours from cold to hot and improve immunotherapy responsiveness. Frontiers in Immunology, 14. 1335256. ISSN 1664-3224

Jones, R.P. orcid.org/0000-0001-5608-001X, Lee, L.Y.W., Corrie, P.G. et al. (2 more authors) (2023) Individualized cancer vaccines versus surveillance after adjuvant chemotherapy for surgically resected high-risk stage 2 and stage 3 colorectal cancer: protocol for a randomized trial. British Journal of Surgery, 110 (12). pp. 1883-1884. ISSN 0007-1323

Kristeleit, R. orcid.org/0000-0003-3825-1326, Plummer, R., Jones, R. et al. (11 more authors) (2023) A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer, 129. pp. 38-45. ISSN 0007-0920

Ng, K.W., Boumelha, J., Enfield, K.S.S. orcid.org/0000-0002-4551-6073 et al. (328 more authors) (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616. pp. 563-573. ISSN 0028-0836

Martínez-Ruiz, C. orcid.org/0000-0002-4817-0565, Black, J.R.M., Puttick, C. et al. (294 more authors) (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616. pp. 543-552. ISSN 0028-0836

Abbosh, C. orcid.org/0000-0002-8983-1382, Frankell, A.M. orcid.org/0000-0002-0341-7878, Harrison, T. et al. (303 more authors) (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616 (7957). pp. 553-562. ISSN 0028-0836

Frankell, A.M. orcid.org/0000-0002-0341-7878, Dietzen, M. orcid.org/0000-0002-6853-7563, Al Bakir, M. orcid.org/0000-0002-0846-8332 et al. (284 more authors) (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616. pp. 525-533. ISSN 0028-0836

Al Bakir, M. orcid.org/0000-0002-0846-8332, Huebner, A. orcid.org/0000-0001-8009-4999, Martínez-Ruiz, C. orcid.org/0000-0002-4817-0565 et al. (283 more authors) (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616. pp. 534-542. ISSN 0028-0836

Hill, W., Lim, E.L., Weeden, C.E. et al. (323 more authors) (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616 (7955). pp. 159-167. ISSN 0028-0836

Al-Sawaf, O. orcid.org/0000-0001-9895-0570, Weiss, J., Skrzypski, M. et al. (302 more authors) (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29 (4). pp. 846-858. ISSN 1078-8956

Karasaki, T. orcid.org/0000-0001-6863-2360, Moore, D.A. orcid.org/0000-0002-6296-1312, Veeriah, S. et al. (288 more authors) (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29 (4). pp. 833-845. ISSN 1078-8956

Danson, S. orcid.org/0000-0002-3593-2890, Sirois, F. orcid.org/0000-0002-0927-277X, Fradley, K. orcid.org/0000-0002-2443-7368 et al. (8 more authors) (2023) Mental health burden for NHS healthcare staff during the COVID-19 pandemic: first results of a longitudinal survey. Heliyon, 9 (3). e13765. ISSN 2405-8440

Peters, S., Letovanec, I., Mauer, M. et al. (15 more authors) (2023) Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. Lung Cancer, 175. pp. 141-151. ISSN 0169-5002

Fennell, D.A. orcid.org/0000-0001-7373-1312, Porter, C., Lester, J. et al. (8 more authors) (2022) Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): a multicentre, randomised, controlled, phase 2 trial. eClinicalMedicine, 52. 101595. ISSN 2589-5370

Woll, P., Gaunt, P., Danson, S. et al. (8 more authors) (2022) Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP) : a randomised, double-blind, placebo-controlled phase II trial. Lung Cancer, 171. pp. 26-33. ISSN 0169-5002

Lee, R.W., Danson, S. orcid.org/0000-0002-3593-2890, Elliot, M. et al. (8 more authors) (2022) Importance of clinical research for the UK's 10-year cancer plan. The Lancet Oncology, 23 (8). pp. 975-978. ISSN 1470-2045

Howard, F. orcid.org/0000-0001-9899-3079, Conner, J., Danson, S. orcid.org/0000-0002-3593-2890 et al. (1 more author) (2022) Inconsistencies in modeling the efficacy of the oncolytic virus HSV1716 reveal potential predictive biomarkers for tolerability. Frontiers in Molecular Biosciences, 9. 889395.

Fennell, D.A. orcid.org/0000-0001-7373-1312, Porter, C., Lester, J. et al. (14 more authors) (2022) Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine, 48. 101432. ISSN 2589-5370

Wu, Y. orcid.org/0000-0003-4080-3935, Biswas, D. orcid.org/0000-0001-9141-5188, Usaite, I. et al. (302 more authors) (2022) A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer. Nature Cancer, 3. pp. 696-709. ISSN 2662-1347

Woll, P.J., Gaunt, P., Danson, S. orcid.org/0000-0002-3593-2890 et al. (8 more authors) (2022) Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP) : a randomised, double-blind, placebo-controlled phase II trial. SSRN. (Submitted)

Fennell, D.A., Griffiths, G., Ottensmeier, C. et al. (4 more authors) (2022) CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. The Lancet Oncology, 23 (1). e14-e15. ISSN 1470-2045

Fennell, D.A., Ewings, S., Ottensmeier, C. et al. (36 more authors) (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology, 22 (11). pp. 1530-1540. ISSN 1470-2045

Peters, S., Danson, S. orcid.org/0000-0002-3593-2890, Ejedepang, D. et al. (19 more authors) (2021) Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung Cancer, 161. pp. 76-85. ISSN 0169-5002

Coen, O., Corrie, P., Marshall, H. et al. (17 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21 (1). 761. ISSN 1471-2407

Kennedy, F., Shearsmith, L., Ayres, M. et al. (5 more authors) (2021) Online monitoring of patient self-reported adverse events in early phase clinical trials : views from patients, clinicians, and trial staff. Clinical Trials, 18 (2). pp. 168-179. ISSN 1740-7745

Crabb, S.J., Danson, S. orcid.org/0000-0002-3593-2890, Catto, J.W.F. orcid.org/0000-0003-2787-8828 et al. (16 more authors) (2021) Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clinical Cancer Research, 27 (7). pp. 1882-1892. ISSN 1078-0432

Merry, E., Marples, M., Danson, S. orcid.org/0000-0002-3593-2890 et al. (7 more authors) (2020) Effect of carboplatin when administered after dacarbazine failure : clinical benefit of sequential therapy. Molecular and Clinical Oncology, 13 (6). 73. pp. 1-4. ISSN 2049-9450

Peters, S., Danson, S. orcid.org/0000-0002-3593-2890, Hasan, B. et al. (35 more authors) (2020) A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC : the European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR trial. Journal of Thoracic Oncology, 15 (10). pp. 1647-1656. ISSN 1556-0864

Fennell, D.A., Danson, S. orcid.org/0000-0002-3593-2890, Woll, P.J. orcid.org/0000-0002-1118-0831 et al. (9 more authors) (2020) Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02) : a phase Ib trial. Clinical Cancer Research, 26 (18). pp. 4748-4755. ISSN 1078-0432

Wyld, L. orcid.org/0000-0002-4046-5940, Bellantuono, I. orcid.org/0000-0001-9994-6987, Tchkonia, T. et al. (6 more authors) (2020) Senescence and cancer : a review of clinical implications of senescence and senotherapies. Cancers, 12 (8). 2134.

Danson, S. orcid.org/0000-0002-3593-2890, Mulvey, M.R., Turner, L. et al. (6 more authors) (2019) An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. Journal of Bone Oncology, 19. 100261. ISSN 2212-1374

Danson, S. orcid.org/0000-0002-3593-2890, Hook, J., Marshall, H. et al. (4 more authors) (2019) Are we over-treating with checkpoint inhibitors? British Journal of Cancer, 121 (8). pp. 629-630. ISSN 0007-0920

Hardy-Werbin, M., Rocha, P., Arpi, O. et al. (13 more authors) (2019) Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. OncoImmunology, 8 (6). e1593810. ISSN 2162-4011

Urbonas, V., Schadendorf, D., Zimmer, L. et al. (11 more authors) (2019) Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology, 30 (2). pp. 317-324. ISSN 0923-7534

Geva, R., Lopez, J.S., Danson, S. orcid.org/0000-0002-3593-2890 et al. (6 more authors) (2018) Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging. ISSN 1619-7070

Chouaid, C., Danson, S. orcid.org/0000-0002-3593-2890, Andreas, S. et al. (15 more authors) (2018) Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer, 124. pp. 310-316. ISSN 0169-5002

Andreas, S., Chouaid, C., Danson, S. orcid.org/0000-0002-3593-2890 et al. (15 more authors) (2018) Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung Cancer, 124. pp. 298-309.

Silva, S., Danson, S., Teare, M.D. et al. (12 more authors) (2018) Genome-wide analysis of circulating cell-free DNA copy number detects active melanoma and predicts survival. Clinical Chemistry, 64 (9). pp. 1338-1346. ISSN 0009-9147

Fennell, D.A., Kirkpatrick, E., Cozens, K. et al. (13 more authors) (2018) CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. TRIALS, 19. 233. ISSN 1745-6215

Arce Vargas, F., Furness, A.J.S., Litchfield, K. et al. (249 more authors) (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33 (4). 649-663.e4. ISSN 1535-6108

Hardy-Werbin, M., Arpi, O., Taus, A. et al. (10 more authors) (2018) Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. OncoImmunology, 7 (2). e1395125. ISSN 2162-402X

Arriola, E., Wheater, M., Galea, I. et al. (13 more authors) (2016) Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer. Journal of Thoracic Oncology, 11 (9). pp. 1511-1521. ISSN 1556-0864

Ahmad, S.S., Qian, W., Ellis, S. et al. (26 more authors) (2015) Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25 (5). pp. 432-442. ISSN 0960-8931

Bird, J., Coleman, P. and Danson, S. (2015) Coping with melanoma-related worry: a qualitative study of the experiences and support needs of patients with malignant melanoma. Journal of Clinical Nursing, 24 (7-8). pp. 937-947. ISSN 0962-1067

Natale, R., Blackhall, F., Kowalski, D. et al. (14 more authors) (2014) Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non-Small-Cell Lung Cancer A Randomized Open-Label Phase II Study. Journal of Thoracic Oncology, 9 (11). pp. 1704-1708. ISSN 1556-0864

Corrie, P., Marshall, A., Dunn, J. et al. (17 more authors) (2014) Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, 15 (6). pp. 620-630. ISSN 1470-2045

Lakshminarayana, P., Danson, S., Suvarna, K. et al. (1 more author) (2007) Atrial and placental melanoma metastasis: a case report and literature review. Journal of Medical Case Reports, 1. 21. ISSN 1752-1947

Clayton, A.J., Danson, S., Jolly, S. et al. (9 more authors) (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. British Journal of Cancer , 91 (4). pp. 639-643. ISSN 0007-0920

Danson, S., Ferry, D., Alakhov, V. et al. (6 more authors) (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer. British Journal of Cancer, 90 (11). pp. 2085-2091. ISSN 0007-0920

Proceedings Paper

Gagg, H., Williams, S., Allen, R. orcid.org/0000-0003-2448-7987 et al. (7 more authors) (2022) F-1286: Ex vivo-led drug discovery in glioblastoma. In: Brain Tumor Research and Treatment. 6th Quadrennial Meeting of the World Federation of Neuro-oncology Societies (WFNOS 2022), 24-27 Mar 2022, Seoul, Korea. Korean Brain Tumor Society; Korea Society for Neuro-Oncology , s240.

Hanna, G., Griffiths, G., Kirkpatrick, E.V. et al. (11 more authors) (2018) CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin. Elsevier , S84-S84.

Garikipati, S., Prakash, A., Alhilali, M. et al. (8 more authors) (2018) Management and outcomes of patients with small cell lung cancer in North Trent. In: Lung Cancer. The 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin . Elsevier , S73-S73.

Low, L., Salawu, A., Bates, E. et al. (7 more authors) (2018) The North Trent experience of administering pembrolizumab to previously treated patients with advanced non-small cell lung cancer. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin, Ireland. Elsevier , S35-S35.

This list was generated on Sat Mar 23 12:56:45 2024 GMT.